Literature DB >> 25699359

Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer.

Masatsune Shibutani, Kiyoshi Maeda, Hisashi Nagahara, Hiroshi Ohtani, Kenji Sugano, Tetsuro Ikeya, Kenjiro Kimura, Ryosuke Amano, Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Masaichi Ohira, Kosei Hirakawa.   

Abstract

BACKGROUND/AIMS: Previous studies have reported that elevated preoperative serum C-reactive protein (CRP) levels are associated with a poor prognosis in patients with various types of cancer. The aim of this study was to evaluate the prognostic significance of the preoperative serum CRP levels in patients with colorectal cancer and determine an appropriate cutoff value of the serum CRP level.
METHODOLOGY: We enrolled 855 patients who underwent surgery for stage I-IV colorectal cancer. The median serum CRP level was 0.13 (range: 0.01-22.8). We set 0.6 as the cutoff value of the serum CRP level based on the receiver operating characteristic curve. The patients were classified into two groups according to the serum CRP level. The prognostic significance of an elevated serum CRP level was evaluated using a multivariate analysis.
RESULTS: The cancer-specific survival was significantly worse in the patients with a high serum CRP level. In particular, more significant differences were observed in the patients with stage IV disease. The multivariate analysis indicated that a high serum CRP level was an independent risk factor for poor survival.
CONCLUSIONS: The preoperative serum CRP level is a convenient biomarker and predictor of a poor prognosis after surgery for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25699359

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Yasuhito Iseki; Tetsuro Ikeya; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

2.  Characteristics of colorectal cancer diagnosed with screening abdominal ultrasonography.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Rumiko Hasegawa; Kazunori Fugo; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Mol Clin Oncol       Date:  2016-05-11

3.  Prognostic value of serum inflammatory markers in colorectal cancer.

Authors:  Sung Chul Lee; Jung Wook Huh; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim; Yong Beom Cho; Yoon Ah Park; Jung Kyong Shin
Journal:  Int J Colorectal Dis       Date:  2020-04-18       Impact factor: 2.571

4.  The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Hiroshi Ohtani; Yasuhito Iseki; Tetsuro Ikeya; Kenji Sugano; Kosei Hirakawa
Journal:  BMC Cancer       Date:  2015-05-02       Impact factor: 4.430

5.  Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer.

Authors:  Jie You; Wen-Yue Liu; Gui-Qi Zhu; Ou-Chen Wang; Rui-Min Ma; Gui-Qian Huang; Ke-Qing Shi; Gui-Long Guo; Martin Braddock; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2015-08-14

6.  The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Yasuhito Iseki; Kosei Hirakawa; Masaichi Ohira
Journal:  Springerplus       Date:  2016-10-18

7.  Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.

Authors:  Li-Na Ma; Xiao-Yan Liu; Zhen-Hui Lu; Li-Gang Wu; Yuan-Yuan Tang; Xia Luo; Yan-Chao Hu; Ting-Ting Yan; Qi Wang; Xiang-Chun Ding; Yan Xie
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

Review 8.  C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.

Authors:  Peter C Hart; Ibraheem M Rajab; May Alebraheem; Lawrence A Potempa
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

9.  Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.

Authors:  Qing Huang; Peng Diao; Chang-Lin Li; Qian Peng; Tianpeng Xie; Yan Tan; Jin-Yi Lang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.